Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBS-008 in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Tinlarebant (Primary)
- Indications Dry age-related macular degeneration; Stargardt disease
- Focus Adverse reactions; First in man; Pharmacokinetics
- 20 Jul 2020 Results presented in a Belite Bio Media Release.
- 03 Jan 2020 Status changed from active, no longer recruiting to completed.
- 15 Oct 2019 Status changed from recruiting to active, no longer recruiting.